2025
3D-DXA reveals significant effects of burosumab on trabecular and cortical skeletal envelopes in symptomatic adults with X-linked hypophosphatemia
Patki R, Carpenter T, Murari K, Parziale S, Deng Y, Humbert L, Picazo M, Insogna K. 3D-DXA reveals significant effects of burosumab on trabecular and cortical skeletal envelopes in symptomatic adults with X-linked hypophosphatemia. Journal Of Bone And Mineral Research 2025, zjaf092. PMID: 40652299, DOI: 10.1093/jbmr/zjaf092.Peer-Reviewed Original ResearchX-linked hypophosphatemiaTrabecular volumetric BMDEffects of burosumabVolumetric BMDAreal BMDSymptomatic adultsFemoral neckHealing of osteomalaciaTrabecular boneCourse of therapyFN strengthHealed osteomalaciaDXA scansCross-sectional momentBurosumab therapyBurosumabRegistration trialsDrug therapyFrequent fracturesSkeletal envelopeDrug treatmentBMDTherapyLower extremitiesTrabecular
2024
The Right Dose: Results of a Patient Advocate–Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life
Loeser A, Kim J, Peppercorn J, Burkard M, Niemierko A, Juric D, Kalinsky K, Rugo H, Glenn L, Hodgdon C, Maues J, Johnson S, Padron N, Parekh K, Lustberg M, Bardia A. The Right Dose: Results of a Patient Advocate–Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life. JCO Oncology Practice 2024, 20: 972-983. PMID: 38518184, DOI: 10.1200/op.23.00539.Peer-Reviewed Original ResearchMetastatic breast cancerTreatment-related side effectsSide effectsDose reductionBreast cancerLow dosesQuality of lifePhase I clinical trialFlexible dosing optionsMaximum tolerated doseDose of drugCourse of therapyIndividual doses of drugsCourse of treatmentPatient-physician discussionsPrescribed doseTolerated doseTargeted therapyDosing optionsAlternative dosingMedical oncologistsDose initiationHigh dosesImprove patient well-beingEffective treatment
2023
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship
Lustberg M, Kuderer N, Desai A, Bergerot C, Lyman G. Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship. Nature Reviews Clinical Oncology 2023, 20: 527-542. PMID: 37231127, PMCID: PMC10211308, DOI: 10.1038/s41571-023-00776-9.Peer-Reviewed Original ResearchConceptsAdverse eventsEvidence-based clinical practice guidelinesChemotherapy-associated adverse eventsNon-pharmacological treatment strategiesAdverse effectsClinical practice guidelinesAdverse treatment effectsCourse of therapyTotality of evidenceQuality of lifeTerms of survivalRisk assessment toolOptimal therapyCancer survivorsRisk factorsOncology practiceTreatment strategiesPractice guidelinesUnderlying biological mechanismsAppropriate managementAnticancer treatmentCancer treatmentEffective interventionsTreatment effectsChemotherapy
2022
YELLOW SUBRETINAL PIGMENT EPITHELIUM DEPOSITS: A NOVEL SIGN IN OCULAR TUBERCULOSIS
Agarwal A, Aggarwal K, Katoch D, Invernizzi A, Arora A, Handa S, Sharma A, Sharma K, Gupta V. YELLOW SUBRETINAL PIGMENT EPITHELIUM DEPOSITS: A NOVEL SIGN IN OCULAR TUBERCULOSIS. Retinal Cases & Brief Reports 2022, 16: 494-499. PMID: 32541431, DOI: 10.1097/icb.0000000000001016.Peer-Reviewed Original ResearchConceptsSubretinal pigment epithelium depositsTubercular posterior uveitisFundus autofluorescenceFluorescein angiographyPosterior uveitisEnhanced-depth imaging optical coherence tomographyInitiation of antitubercular therapyTertiary referral eye centreAcid-fast bacilliInvasive tissue biopsiesOptical coherence tomographyCourse of therapyDiagnostic signsLate hyperfluorescenceOcular tuberculosisFundus photographyAntitubercular therapyClinical suspicionRetrospective reviewEye CentreImaging findingsNoninfective etiologyTissue biopsiesCoherence tomographyPatientsArtificial Intelligence (AI) to improve chronic pain care: Evidence of AI learning
Piette J, Newman S, Krein S, Marinec N, Chen J, Williams D, Edmond S, Driscoll M, LaChappelle K, Maly M, Kim H, Farris K, Higgins D, Kerns R, Heapy A. Artificial Intelligence (AI) to improve chronic pain care: Evidence of AI learning. Intelligence-Based Medicine 2022, 6: 100064. DOI: 10.1016/j.ibmed.2022.100064.Peer-Reviewed Original ResearchPatient interactionsPatient subgroupsInteractive voice response callsPain-related interferenceComparative effectiveness trialChronic pain careCourse of therapyPedometer step countsDisease management programsCognitive behavioral therapyCBT-CPChronic painMore patientsPain careTreatment modalitiesTreatment recommendationsEffectiveness trialPatientsStep countBehavioral therapyClinician timeWeeksTherapy sessionsMethods DataTherapist feedback
2020
Using real-world data to investigate time-dependent blood count response to PD-1 and PD-L1 inhibitors and its impact on survival in advanced non-small cell lung cancers.
Ayers K, Liu Z, Ma M, Lee K, Newman S, Li L, Zhou X, Mullaney T, Redfern A, Jappe W, Zimmerman M, Prentice T, Oh W, Schadt E, Li D, Chen R. Using real-world data to investigate time-dependent blood count response to PD-1 and PD-L1 inhibitors and its impact on survival in advanced non-small cell lung cancers. Journal Of Clinical Oncology 2020, 38: e21514-e21514. DOI: 10.1200/jco.2020.38.15_suppl.e21514.Peer-Reviewed Original ResearchPD1/PD-L1 therapyPD-L1 therapyOverall survivalLung cancer patientsNeutrophil levelsCourse of therapyTreatment discontinuationRed blood cellsCancer patientsAdvanced non-small cell lung cancerAdvanced non-small cell lung cancer (NSCLC) patientsNon-small cell lung cancer patientsNon-small cell lung cancerMount Sinai Health SystemCell lung cancer patientsComplete blood count dataBlood cellsAbnormal baseline levelsHigher neutrophil levelsImmune checkpoint inhibitorsRetrospective cohort studySinai Health SystemPD-L1 inhibitorsCell lung cancerPoor overall survival
2017
Incidence of and Predictors for Early Discontinuation of Biological Therapies in Veteran Patients with Inflammatory Bowel Disease
Feagins LA, Waljee A, Hou JK, Gu P, Kanjo S, Rudrapatna V, Cipher DJ, Govani S, Gaidos J. Incidence of and Predictors for Early Discontinuation of Biological Therapies in Veteran Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2017, 23: 1434-1439. PMID: 28570429, DOI: 10.1097/mib.0000000000001145.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseBiological therapyAdverse drug reactionsConcomitant thiopurinesPrimary nonresponseEarly discontinuationBowel diseaseDrug reactionsDiagnosis of IBDBiological agentsFirst biological agentRetrospective cohort studyInitiation of therapyCourse of therapyVA hospital systemIleocolonic diseaseVA cohortCohort studyVeteran patientsMedical recordsRisk factorsCommon reasonPatientsDiscontinuationTherapy
2013
Validation Of a Brief Arsenic Trioxide (ATO)-Based Consolidation Chemotherapy In The Upfront Management Of Acute Promyelocytic Leukemia (APL): Less Anthracycline Exposure and Faster Completion Of Consolidation Therapy With Equivalent Survival
Leech M, Stewart M, Zhang X, Bashey A, Holland H, Solomon S, Carraway H, Smith B, Morris L, Gore S, Zeidan A. Validation Of a Brief Arsenic Trioxide (ATO)-Based Consolidation Chemotherapy In The Upfront Management Of Acute Promyelocytic Leukemia (APL): Less Anthracycline Exposure and Faster Completion Of Consolidation Therapy With Equivalent Survival. Blood 2013, 122: 3963. DOI: 10.1182/blood.v122.21.3963.3963.Peer-Reviewed Original ResearchAcute promyelocytic leukemiaLeukemia-free survivalComplete remissionOverall survivalAnthracycline exposureConsolidation chemotherapyMaintenance therapyIntensive therapyOriginal trialM2/dATRA-ATO combinationContinuous infusion cytarabineSignificant cardiac toxicityLow-risk diseaseMonths of therapyHigh-risk diseaseKaplan-Meier methodologyOriginal clinical trialsCourse of therapyCompletion of protocolTrans retinoic acidChemotherapy consolidationConsolidation therapyInduction therapyIntravenous daunorubicinMachine learning for predicting the response of breast cancer to neoadjuvant chemotherapy
Mani S, Chen Y, Li X, Arlinghaus L, Chakravarthy A, Abramson V, Bhave S, Levy M, Xu H, Yankeelov T. Machine learning for predicting the response of breast cancer to neoadjuvant chemotherapy. Journal Of The American Medical Informatics Association 2013, 20: 688-695. PMID: 23616206, PMCID: PMC3721158, DOI: 10.1136/amiajnl-2012-001332.Peer-Reviewed Original ResearchConceptsNeoadjuvant chemotherapyFeature selectionCycles of NACPredictive model buildingTime most patientsBreast cancer patientsImportant clinical problemCourse of therapyMachine learningDynamic contrast-enhanced MRIContrast-enhanced MRIQuantitative dynamic contrast-enhanced MRIMost patientsTreatment regimenCancer patientsClinical variablesTherapeutic responseBreast cancerPredictive modeling approachClinical problemData show promiseLogistic regressionPatientsMachineDiffusion-weighted MRI data
2008
Persistent and Relapsing Babesiosis in Immunocompromised Patients
Krause PJ, Gewurz BE, Hill D, Marty FM, Vannier E, Foppa IM, Furman RR, Neuhaus E, Skowron G, Gupta S, McCalla C, Pesanti EL, Young M, Heiman D, Hsue G, Gelfand JA, Wormser GP, Dickason J, Bia FJ, Hartman B, Telford SR, Christianson D, Dardick K, Coleman M, Girotto JE, Spielman A. Persistent and Relapsing Babesiosis in Immunocompromised Patients. Clinical Infectious Diseases 2008, 46: 370-376. PMID: 18181735, DOI: 10.1086/525852.Peer-Reviewed Original ResearchConceptsCase patientsAntibabesial treatmentClinical courseControl subjectsBlood smearsRetrospective case-control studyOptimal treatment regimenStandard antimicrobial therapyMalaria-like illnessBabesia microti infectionMost cases patientsCase-control studyCourse of therapyB-cell lymphomaAdministration of atovaquoneImmunologic statusStandard therapyAntimicrobial regimenSuch patientsTreatment regimenMicroti infectionAntimicrobial therapyPersistent infectionCell lymphomaAcute babesiosis
2007
Alefacept for the treatment of psoriasis and other dermatologic diseases
Strober B, Menon K. Alefacept for the treatment of psoriasis and other dermatologic diseases. Dermatologic Therapy 2007, 20: 270-276. PMID: 17970892, DOI: 10.1111/j.1529-8019.2007.00140.x.Peer-Reviewed Original ResearchConceptsT cellsSeverity Index (PASI) 75 responseMemory effector T cellsNovel biologic agentsLong-term remissionEffector T cellsTreatment of psoriasisAntigen presenting cellsPathophysiology of psoriasisCourse of therapyDimeric fusion proteinPASI 75Plaque psoriasisAdverse eventsPsoriasis AreaBiologic agentsMore patientsLabel useImmunologic activationPresenting cellsIntramuscular injectionDosing strategiesAlefaceptDermatologic diseasesPsoriasis
2006
Biologic Correlates of Response and Survival in Patients with Cutaneous T-Cell Lymphoma Treated with Denileukin Diftitox
Chin KM, Foss FM. Biologic Correlates of Response and Survival in Patients with Cutaneous T-Cell Lymphoma Treated with Denileukin Diftitox. Clinical Lymphoma Myeloma & Leukemia 2006, 7: 199-204. PMID: 17229335, DOI: 10.3816/clm.2006.n.059.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsCD4-Positive T-LymphocytesClinical Trials as TopicDiphtheria ToxinFemaleHumansInterleukin-2Interleukin-2 Receptor alpha SubunitLymphoma, T-Cell, CutaneousMaleMiddle AgedMycosis FungoidesReceptors, Interleukin-2Recombinant Fusion ProteinsSkin NeoplasmsTreatment OutcomeConceptsCutaneous T-cell lymphomaAdvanced stage diseaseT-cell lymphomaDenileukin diftitoxMedian survivalBiologic correlatesAdvanced-stage cutaneous T-cell lymphomaResponse ratePhase III registration trialNumber of CD4Single-center seriesAbsolute lymphocyte countOverall response rateT cell populationsCourse of therapyLymphocyte countClinical responseLymphocyte populationsDisease progressionDiftitoxPatientsRegistration trialsHuman interleukinLactate dehydrogenaseSurvival
2002
Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
Cragg LH, Andreeff M, Feldman E, Roberts J, Murgo A, Winning M, Tombes MB, Roboz G, Kramer L, Grant S. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia. Clinical Cancer Research 2002, 8: 2123-33. PMID: 12114412.Peer-Reviewed Original ResearchConceptsDose-limiting toxicityPhase I trialComplete remissionCorrelative laboratory studiesI trialAcute leukemiaSplit courseContinuous infusionVivo administrationBryostatin 1Ara-C dose levelsAutologous bone marrow transplantationMajor dose-limiting toxicityEx vivoRefractory acute leukemiaUnfavorable prognostic characteristicsHigh-risk featuresLeukemia-free survivalBone marrow transplantationCourse of therapyPKC activityTransfusion requirementsRefractory leukemiaRefractory/Latter patients
2000
Sterility of epidural solutions—Recommendations for cost-effective use
Sevarino F, Pizarro C, Sinatra R. Sterility of epidural solutions—Recommendations for cost-effective use. Regional Anesthesia & Pain Medicine 2000, 25: 368-371. PMID: 10925932, DOI: 10.1053/rapm.2000.4148.Peer-Reviewed Original ResearchAre selective COX-2 inhibitors nephrotoxic?
Perazella M, Eras J. Are selective COX-2 inhibitors nephrotoxic? American Journal Of Kidney Diseases 2000, 35: 937-940. PMID: 10793030, DOI: 10.1016/s0272-6386(00)70266-6.Peer-Reviewed Original ResearchConceptsHigh-risk patientsRenal insufficiencySelective cyclooxygenase-2 enzyme inhibitorsSuch high-risk patientsNonsteroidal anti-inflammatory drugsSelective COX-2 inhibitorsChronic renal impairmentChronic renal insufficiencyAcute renal failureAcute renal insufficiencyAdverse gastrointestinal effectsCyclooxygenase-2 enzyme inhibitorsAnti-inflammatory drugsCourse of therapyCOX-2 inhibitorsPain syndromeRenal impairmentRenal failureGastrointestinal effectsNephrotoxic potentialInflammatory diseasesEnzyme inhibitorsPatientsInsufficiencyInhibitors
1998
THE VALUE OF UNENHANCED HELICAL COMPUTERIZED TOMOGRAPHY IN THE MANAGEMENT OF ACUTE FLANK PAIN
DALRYMPLE N, VERGA M, ANDERSON K, BOVE P, COVEY A, ROSENFIELD A, SMITH R. THE VALUE OF UNENHANCED HELICAL COMPUTERIZED TOMOGRAPHY IN THE MANAGEMENT OF ACUTE FLANK PAIN. Journal Of Urology 1998, 159: 735-740. PMID: 9474137, DOI: 10.1016/s0022-5347(01)63714-5.Peer-Reviewed Original ResearchConceptsAcute flank painUnenhanced helical computerized tomographyHelical computerized tomographyFlank painAdditional imaging studiesAdditional imagingComputerized tomographyRetrograde urographyImaging studiesSpontaneous stone passageFalse-negative examinationsLong-term outcomesCourse of therapyUreteral stone diseaseUnenhanced computerized tomographyUreteroscopic stone extractionClinical followupCT findingsNephrostomy catheterStone passageUreteral obstructionExcretory urographyFinal diagnosisMedical recordsStone diseaseTHE VALUE OF UNENHANCED HELICAL COMPUTERIZED TOMOGRAPHY IN THE MANAGEMENT OF ACUTE FLANK PAIN
DALRYMPLE N, VERGA M, ANDERSON K, BOVE P, COVEY A, ROSENFIELD A, SMITH R. THE VALUE OF UNENHANCED HELICAL COMPUTERIZED TOMOGRAPHY IN THE MANAGEMENT OF ACUTE FLANK PAIN. Journal Of Urology 1998, 159: 735-740.. DOI: 10.1097/00005392-199803000-00026.Peer-Reviewed Original ResearchAcute flank painUnenhanced helical computerized tomographyHelical computerized tomographyFlank painAdditional imaging studiesAdditional imagingComputerized tomographyRetrograde urographyImaging studiesSpontaneous stone passageFalse-negative examinationsLong-term outcomesCourse of therapyUreteral stone diseaseUnenhanced computerized tomographyUreteroscopic stone extractionClinical followupCT findingsNephrostomy catheterStone passageUreteral obstructionExcretory urographyFinal diagnosisMedical recordsStone disease
1997
Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy
Demark-Wahnefried W, Hars V, Conaway, Havlin K, Rimer B, McElveen G, Winer E. Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy. American Journal Of Clinical Nutrition 1997, 65: 1495-1501. PMID: 9129482, DOI: 10.1093/ajcn/65.5.1495.Peer-Reviewed Original ResearchConceptsBreast cancer patientsAdjuvant chemotherapyCancer patientsPhysical activityEnergy intakeWeight gainBreast cancerBody compositionCompletion of chemotherapyCommon side effectsCourse of therapyDiet-induced thermogenesisQuality of lifePremenopausal patientsLeucovorin chemotherapyChemotherapySide effectsStage IBaseline levelsPatientsImpairs survivalEnergy expenditureOptimal interventionIntakeComplete data
1990
Psychotherapist Orientation and Expectations for Liked and Disliked Patients
Lehman A, Salovey P. Psychotherapist Orientation and Expectations for Liked and Disliked Patients. Professional Psychology Research And Practice 1990, 21: 385-391. DOI: 10.1037/0735-7028.21.5.385.Peer-Reviewed Original Research
1989
Gentamicin nephrotoxicity in extrahepatic cholestasis: Modulation by dietary calcium
Vakil N, Abu‐Alfa A, Mujais S. Gentamicin nephrotoxicity in extrahepatic cholestasis: Modulation by dietary calcium. Hepatology 1989, 9: 519-524. PMID: 2925154, DOI: 10.1002/hep.1840090402.Peer-Reviewed Original ResearchConceptsDietary calcium supplementationGentamicin nephrotoxicityCalcium supplementationLigation animalsExtrahepatic cholestasisCommon bile duct ligation groupCommon bile duct ligation ratsBile duct ligation groupCommon bile duct obstructionBile duct ligation ratsMale Sprague-Dawley ratsUrinary calcium excretionHigh calcium dietBile duct obstructionBile duct ligationSprague-Dawley ratsCourse of therapyExperimental extrahepatic cholestasisSevere azotemiaCalcium excretionConcurrent administrationDuct obstructionGentamicin administrationSham ratsDietary calcium
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply